# RX-3117 in Combination With Abraxane® in Subjects With Metastatic Pancreatic Cancer

> **NCT03189914** · PHASE1,PHASE2 · COMPLETED · sponsor: **Processa Pharmaceuticals** · enrollment: 46 (actual)

## Conditions studied

- Metastatic Pancreatic Cancer

## Interventions

- **DRUG:** RX-3117

## Key facts

- **NCT ID:** NCT03189914
- **Lead sponsor:** Processa Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-10-02
- **Primary completion:** 2019-10-01
- **Final completion:** 2019-11-21
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2023-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03189914

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03189914, "RX-3117 in Combination With Abraxane® in Subjects With Metastatic Pancreatic Cancer". Retrieved via AI Analytics 2026-05-31 from https://api.ai-analytics.org/clinical/NCT03189914. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*